Click here to return to the Reference Table

Category: Carcinomas
Cancer type: Nasopharyngeal
Descriptor: Therapeutic Development

Reference Number: 967
Lui VW, Wong EY, Ho K, Ng PK, Lau CP, Tsui SK, Tsang CM, Tsao SW, Cheng SH, Ng MH, Ng YK, Lam EK, Hong B, Lo KW, Mok TS, Chan AT, Mills GB. Inhibition of c-Met downregulates TIGAR expression and reduces NADPH production leading to cell death. Oncogene. 30, 1127-34 (2011)
PubMed link      E-mail link

Reference Number: 1163
Lau PC, Wong EY. Targeting MET by tyrosine kinase inhibitor suppresses growth and invasion of nasopharyngeal carcinoma cell lines. Pathol Oncol Res. 18, 357-63 (2012)
PubMed link      E-mail link

Reference Number: 1448
Liu T1, Li Q2, Sun Q1, Zhang Y1, Yang H1, Wang R1, Chen L1, Wang W3. MET inhibitor PHA-665752 suppresses the hepatocyte growth factor-induced cell proliferation and radioresistance in nasopharyngeal carcinoma cells. Biochem Biophys Res Commun. 449, 49-54 (2014)
PubMed link      E-mail link

Reference Number: 1730
Li YQ, Ren XY, He QM, Xu YF, Tang XR, Sun Y, Zeng MS, Kang TB, Liu N, Ma J MiR-34c suppresses tumor growth and metastasis in nasopharyngeal carcinoma by targeting MET. Cell Death Dis. 6, e1618 (2015)
PubMed link      E-mail link